The WuXi Advanced Therapies Story: Cell and Gene Since 1982
Solving today’s commercialization challenges by leveraging over three decades of experience to deliver tomorrow’s biopharmaceuticals.
ViroMed Laboratories established in Minneapolis, offering clinical diagnostics with viral focus.
Philadelphia (Camden, NJ) location established as Quality Biotech, offering biopharmaceutical testing.
1996 - 1998
Axios and Quality Biotech acquired by ViroMed.
St. Paul location opened.
WuXi Pharmatech is formed in China by Dr. Ge Li.
St. Paul, Atlanta, and Philadelphia sites become AppTec Laboratory Services, Inc.
Opened League Island 1. Manufactured first GMP lot for cell therapy in PHL.
WuXi PharmaTech buys AppTec, and forms WuXi AppTec.
PHL operations continue to manufacture cell banks and provide testing services for biopharmaceuticals.
Philadelphia begins offering integrated advanced therapies testing and manufacturing services.
Expanded advanced therapies production (clinical & commercial scale) with the opening of 2 new facilities for cell therapy & gene therapy/viral vector manufacturing.
Launched WuXi Hyper-PRO, Viral Vector Production Platform for rapid entry into first in human clinical trials.
Selected as the GMP manufacturing partner for advanced therapies through the California Institute for Regenerative Medicine (CIRM) funded IQVIA Stem Cell Center.
WuXi AppTec spins out advanced therapies manufacturing and testing operations in the US into a separate Business Unit; WuXi Advanced Therapies.
Nohla Therapeutics, a Seattle-based clinical stage cell therapy company entered into a commercial agreement with WuXi Advanced Therapies for the production of its hematopoietic stem and progenitor cell product.
Above: Advanced Therapies HQ, League Island 2 (Philadelphia, PA)
Above: Rouse Poulevard 400 (Philadelphia, PA)
Above: League Island 2 (Philadelphia, PA)
Above: Oxgene (Oxford, UK)
Professionals from multiple disciplines working together to deliver tomorrow’s therapies.
Quality Assurance/QC Analytical